Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 26;12(9):12353. doi: 10.1002/jev2.12353

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Characterization of isolated EV‐enriched fractions. (a) Transmission electron microscopy of AMSC‐derived EV‐enriched fraction. Arrows indicate EVs with a cup‐shape morphology (magnification of 30000×; scale bar = 100 nm). (b) Dynamic light scattering of isolated EV‐enriched fraction (a representative sample with three consecutive runs), indicating a homogeneous size distribution with an average diameter of 169.6 ± 5.14 nm (average PDI of 0.24 ± 0.02). (c) A scatter plot of fluorescence intensity against diameter of particles bound to CD63 antibodies on ExoView chips, normalized to non‐specific binding of proteins bound to mouse IgG (MIgG). (d) ExoView analysis of EV surface markers (CD9, CD63, CD81), internal EV marker of Syntenin‐1 and negative marker of GRP94. (e) Colocalization pie chart for the isolated particle fractions bound to CD63 antibodies on ExoView chips, showing a significant portion of colocalized particles expressing two or more EV‐specific markers (2.3 × 10⁸ total particles bound to CD63).